BDRX_OUT_1 [2025-04-04 04:20:40 -0400] 3328 Bytes | 933 tokens | Cum: 933 tkns (11.66% of 8k)
==========================================================================

Alright, let’s light it up, because it's 4:20:39 AM on Fri Apr 04, 2025 -0400, and I'm charging into Biodexa Pharmaceuticals (BDRX), popping from 1.47 to 1.8. Is this our star stock of the day, or just a quick blip on the radar? I've got the scoop—time to analyze!

--- COMPANY PROFILE ---
Company: Biodexa Pharmaceuticals (BDRX)
IPO: 2015-12-07 (9 Years Ago)
Market Cap: $802,310
Shares Outstanding: 6,685,920,000
Exchange: XNAS
Description: Biodexa Pharmaceuticals PLC is a drug delivery technology company focused on improving the bio-delivery and bio-distribution of medicines. The company combines approved and developed medications with its proprietary and drug delivery technologies to provide compelling products that have the potential to powerfully impact the lives of patients.

Here’s the first list of news for Biodexa Pharmaceuticals:

C1 - Mar-19-25 07:00AM - With Fast Track Designation in Hand, a Successful Protocol Discussion with FDA, and CROs in Place, Biodexa is on Track to Initiate its Funded Phase 3 Trial in FAP Next Quarter
C2 - Mar-10-25 08:30AM - Biodexa Announces Successful Outcome of a Type C Meeting with FDA Regarding the Phase 3 Program for eRapa in FAP
C3 - Mar-06-25 08:30AM - Biodexa Announces Appointment of Precision for Medicine LLC as CRO for European Component of Phase 3 Study of eRapa in FAP
C4 - Feb-24-25 08:30AM - Biodexa Announces Allowance of U.S. Patent Covering Oral Rapamycin Nanoparticle Preparations ("eRapa") and Use
C5 - Feb-19-25 06:00AM - Presenting on the Emerging Growth Conference 79 Day 2 on February 19 Register Now
C6 - Feb-13-25 08:30AM - Biodexa Pharmaceuticals PLC to Present at the Emerging Growth Conference on February 19, 2025
C7 - Feb-12-25 07:30AM - Following Positive Phase 2 Results and Orphan Drug Designation, Biodexa's FAP Drug Receives FDA Fast Track Status
C8 - Feb-10-25 08:30AM - Biodexa Receives US FDA Fast Track Designation for eRapa in Familial Adenomatous Polyposis

Prior AI Reports for BDRX:
1. 2025-04-02 – Score: 25 – Target: 1.8200 – Highs: 1.6800 / 1.4900 / –
company-struggles-amid-steep-sales-decline-low-market-score
2. 2025-03-19 – Score: 30 – Target: 2.6000 – Highs: 2.6500 / 2.2000 / 1.94
significant-sales-drop-questions-long-term-viability

(Note: Highs = Same day / 2nd day / 3rd day)

GUIDELINES FOR AI:
==============

1) You are the **AI analyst-investigator**. I am **ScanScor**, a unified document retrieval and reporting system.
Your role is to examine all available company data and draw sound conclusions.

2) To request additional information, refer to any listed documents using their reference codes.
The company under analysis is: Biodexa Pharmaceuticals (BDRX).

3) As the analysis proceeds, continue reviewing documents until you feel confident in your judgment.
When ready, you will:
- Write a brief summary
- Generate a headline
- Assign a MARKET_SCORE[XX]
- Set a PRICE_TARGET[XX]

4) For now, restrict your response to just **three tokens**.
To request a document, reply with its reference code(s), such as:
- `C1`, `C2`, `C3`, etc.
- To load more documents, reply with: `NEX`

News articles, SEC filings, and key metrics will be revealed in subsequent prompts.
Stay focused. Gather evidence. Continue until your conclusions are clear.

BDRX_OUT_3 [2025-04-04 04:20:41 -0400] 1099 Bytes | 272 tokens | Cum: 1208 tkns (15.10% of 8k)
==========================================================================

Showing C1 (chunk 1 of 12): C1:
**With Fast Track Designation in Hand, a Successful Protocol Discussion with FDA, and CROs in Place, Biodexa is on Track to Initiate its Funded Phase 3 Trial in FAP Next Quarter**
Date: Mar-19-25 07:00AM
Source: (ACCESSWIRE)
URL: https://www.accesswire.com/viewarticle.aspx?id=1001827

The first and only All-in-one subscription platform offering
all of your PR Distribution and Media Outreach Tools in one
single solution.Monthly & Annual Subscriptions.

Find & create journalist lists with the most up to date database in the industry.

Personalize and customize your pitch for maximum engagement.

Discover your brand, industry, and competitor mentions.

The first and only All-in-one subscription platform that offers you the ability
to manage all of your IR communications needs from a single
source.Explore our IR subscriptions

Ensure your IR Site is accessible for your entire audie

--> You can ask for 1) More of this item with: MOR, 2) the NEXt section with: NEX, or 3) a different item by it's handle (ex. C3, S2) (only 3 chars don't summarize yet)

BDRX_OUT_5 [2025-04-04 04:20:42 -0400] 857 Bytes | 255 tokens | Cum: 1465 tkns (18.31% of 8k)
==========================================================================

We present this news so you can catch the big movers from recently breaking news.
Here's a list of news articles you can literally read just by asking.
Usually the first item is the most important.

A1 - 2025-04-03T20:20:23Z - Nanotechnology Stocks To Follow Today - April 1st...
A2 - 2025-04-02T21:05:37Z - 12 Health Care Stocks Moving In Wednesday's After-Market Session - Aptevo Therapeutics (NASDAQ:APVO)...
A3 - 2025-04-01T20:00:54Z - Best Nanotechnology Stocks To Research - March 31st...
A4 - 2025-03-31T20:04:21Z - Promising Nanotechnology Stocks To Keep An Eye On - March 30th...
A5 - 2025-03-30T20:02:51Z - Promising Nanotechnology Stocks To Research - March 29th...

Request an article by its reference number. (Ex., "A1" gets the first item)
You may also say NEX to go to the next listing.
Response to this prompt limited to 3 chars.

BDRX_OUT_7 [2025-04-04 04:20:43 -0400] 1098 Bytes | 273 tokens | Cum: 1740 tkns (21.75% of 8k)
==========================================================================

Showing A1 (chunk 1 of 8): A1:
**Nanotechnology Stocks To Follow Today - April 1st**Date: 2025-04-03Source: {'uri': 'marketbeat.com', 'dataType': 'news', 'title': 'Market Beat'}URL: https://www.marketbeat.com/instant-alerts/nanotechnology-stocks-to-follow-today-april-1st-2025-04-01/OSI Systems, NVE, Clene, Virpax Pharmaceuticals, and Biodexa Pharmaceuticals are the five Nanotechnology stocks to watch today, according to MarketBeat's stock screener tool. Nanotechnology stocks are shares of companies that research, develop, or commercialize products using materials and technologies at the nanoscale level, typically measured in billionths of a meter. These companies often work on innovations in electronics, healthcare, energy, and materials science, making their stocks an appealing choice for investors interested in cutting-edge technological advancements. These companies had the highest dollar trading volume of any

--> You can ask for 1) More of this item with: MOR, 2) the NEXt section with: NEX, or 3) a different item by it's handle (ex. C3, S2) (only 3 chars don't summarize yet)

BDRX_OUT_9 [2025-04-04 04:20:44 -0400] 1203 Bytes | 366 tokens | Cum: 2108 tkns (26.35% of 8k)
==========================================================================

This is our final list of news.
News AI can literally read just by asking.
Don't miss the breaking news!

B1 - 2024-10-29T20:00:00Z - BDRX INVESTOR ALERT: Bronstein, Gewirtz and Grossman, LLC Announces an Investigation into Biodexa Pharmaceuticals Plc and Encourages Investors to Contact the Firm
B2 - 2024-10-23T20:00:00Z - BDRX INVESTOR ALERT: Bronstein, Gewirtz and Grossman, LLC Announces an Investigation into Biodexa Pharmaceuticals Plc and Encourages Investors to Contact the Firm
B3 - 2024-07-12T09:35:41Z - Why Ericsson Shares Are Trading Higher; Here Are 20 Stocks Moving Premarket - Benzinga
B4 - 2024-07-11T18:02:49Z - Why ConAgra Brands Shares Are Trading Lower? Here Are Other Stocks Moving In Thursday's Mid-Day Session - Benzinga
B5 - 2024-07-02T12:30:00Z - Positive Phase 1 Clinical Data of MTX110 in DMG Brain Cancer Demonstrating Increased Survival Presented at ISPNO 2024
B6 - 2024-06-24T12:30:00Z - Biodexa Announces Positive Phase 2 Clinical Trial Results of eRapa™ at 12 months in Familial Adenomatous Polyposis (FAP)

Request an article by its reference number. (Ex., "B1" gets the first item)
You can say NEX to go to the next listing.
Response limited to 3 chars.

BDRX_OUT_11 [2025-04-04 04:20:47 -0400] 836 Bytes | 252 tokens | Cum: 2362 tkns (29.53% of 8k)
==========================================================================

Showing B1 (chunk 1 of 1): B1:
**BDRX INVESTOR ALERT: Bronstein, Gewirtz and Grossman, LLC Announces an Investigation into Biodexa Pharmaceuticals Plc and Encourages Investors to Contact the Firm**Date: Unknown DateSource: Unknown SourceURL: https://www.globenewswire.com/news-release/2024/10/29/2971185/9788/en/BDRX-INVESTOR-ALERT-Bronstein-Gewirtz-and-Grossman-LLC-Announces-an-Investigation-into-Biodexa-Pharmaceuticals-Plc-and-Encourages-Investors-to-Contact-the-Firm.htmlBiodexa Pharmaceuticals Plc reported updated data on a Phase 1 study of its drug MX110 in the treatment of recurrent glioblastoma, with two out of four patients in the study now deceased.

--> You can ask for 1) More of this item with: MOR, 2) the NEXt section with: NEX, or 3) a different item by it's handle (ex. C3, S2) (only 3 chars don't summarize yet)

BDRX_OUT_13 [2025-04-04 04:20:47 -0400] 238 Bytes | 59 tokens | Cum: 2499 tkns (31.24% of 8k)
==========================================================================

This is our list of SEC filings.
If empty, the search returned no recent filings.

Request filing by its reference number. (Ex., "S1" gets the first item)
You can say NEX to go to the next listing.
Response limited to 3 chars.

BDRX_OUT_15 [2025-04-04 04:21:04 -0400] 3902 Bytes | 948 tokens | Cum: 3450 tkns (43.12% of 8k)
==========================================================================

This is our set of metrics.
Please analyze the numbers.

+-------------------+-----------------------+------------------------+-------------------------+
| Volume: 161,876 | Perf Month: -50.84% | Option/Short: No / Yes | Sales Y/Y TTM: -83.72% |
+-------------------+-----------------------+------------------------+-------------------------+
| Avg Volume: 1.56M | Perf Quarter: -63.70% | Short Float: - | ROE: -96.61% |
+-------------------+-----------------------+------------------------+-------------------------+
| Rel Volume: 0.10 | Index: - | Short Ratio: 0.04 | ROI: -75.99% |
+-------------------+-----------------------+------------------------+-------------------------+
| RSI (14): 34.54 | Market Cap: 0.85M | Short Interest: 0.06M | Sales Surprise: 538.55% |
+-------------------+-----------------------+------------------------+-------------------------+
| ATR (14): 0.35 | Shs Outstand: 0.36M | Beta: 1.20 | EPS Surprise: -49.55% |
+-------------------+-----------------------+------------------------+-------------------------+
| SMA20: -20.81% | Shs Float: - | Sales Q/Q: -100.00% | P/E: - |
+-------------------+-----------------------+------------------------+-------------------------+
| SMA50: -53.50% | Inst Own: 1.27% | Sales past 5Y: - | Earnings: - |
+-------------------+-----------------------+------------------------+-------------------------+
| SMA200: -83.10% | Insider Own: - | Employees: - | |
+-------------------+-----------------------+------------------------+-------------------------+
| Perf Week: 13.95% | Insider Trans: - | Debt/Eq: 0.04 | |
+-------------------+-----------------------+------------------------+-------------------------+

The next section covers any insider trading if any are accessible.

[Company Financial Summary]
[Company Details]
Name: N/A
Market Cap: N/A
Shares Outstanding: N/A
Sector: N/A

[Financial Statements - Latest Quarter]
Total Assets: N/A
Total Liabilities: N/A
Total Equity: N/A
Revenue (Quarter): N/A
Net Income: N/A
Earnings Per Share (EPS): N/A

[Price Metrics - Last 30 Days]
Latest Close: 1.47
Average Volume: 3166404.41
30-Day High: 3.11
30-Day Low: 1.2
No detailed financial data available.
==== END OF FINANCIAL REPORT ====

You are now requested to make a summary analysis.
Do not say you lacked information. Save that for the final survey.

Now complete this report with the following:

1) Brief Summary: Explain your findings in one well-worded paragraph.

2) MARKET_SCORE: Estimate a number between 1 and 100 to represent the likelihood of an upward price move over the next day, week, or longer. Use the format: MARKET_SCORE[XX]
Weigh all relevant data —- news, SEC filings, fundamentals, and metrics —- and assign each element appropriate weight to calculate a general MARKET_SCORE[XX].
This score should be grounded in objective reasoning and guided by your analytical judgment.
XX must be a whole number between 1 and 100.

3) PRICE_TARGET: The current price of {ticker} is {current_price}.
If you believe it’s likely to rise, calculate a reasonable new price target.
For example, if you expect a 50% increase, say: PRICE_TARGET[{increased_price}]
You are encouraged to reference prior price performance when making this estimate.

4) AI_RPT_HEADLINE: Provide a thought-provoking headline (8–12 words) summarizing the situation.
Examples:
- AI_RPT_HEADLINE[{co_name} makes news with FDA approval fueling high investor optimism]
- AI_RPT_HEADLINE[Declining sales plague {ticker}, worsening an already negative outlook]

Return only:
1) Brief Summary
2) MARKET_SCORE[]
3) PRICE_TARGET[]
4) AI_RPT_HEADLINE[]

BDRX_OUT_17 [2025-04-04 04:21:06 -0400] 687 Bytes | 169 tokens | Cum: 3943 tkns (49.29% of 8k)
==========================================================================

Finally, if more data could have improved your confidence which would you have chosen? **Choose one option:**
-> X0 <- Nothing more would have helped my analysis
-> X1 <- More news listings
-> X2 <- More SEC filing extractions (10-K, 10-Q, 8-K) Financials, risk disclosures, and business changes
-> X3 <- More SEC Insider trading extractions (Form 3, 4, 5) Direct buys/sells from executives and institutions
-> X4 <- Broader sector & market news
-> X5 <- Your past analysis on similar companies (specify metrics)
-> X6 <- More financial metrics
-> X7 <- Your past analysis on this company
-> X8 <- Something altogether different (explain...)

BDRX_IN_19 [2025-04-04 04:21:06 -0400] 126 Bytes | 29 tokens | Cum: 4002 tkns (50.02% of 8k)
==========================================================================

====================================
[2025-04-04 04:21:06] # Analysis Completed
Elapsed Time: 26.96 seconds